A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of YKST02 as Monotherapy or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus
Latest Information Update: 13 Apr 2026
At a glance
- Drugs YK 012 (Primary) ; YKST 02 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
Most Recent Events
- 13 Apr 2026 New trial record